SMS Lifesciences India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 25, 2025, 8:10 pm

Competitors of SMS Lifesciences India Ltd

All Competitor Stocks of SMS Lifesciences India Ltd

Quarterly Result

Last Updated: May 31, 2025, 7:44 am

Below is a detailed analysis of the quarterly data for SMS Lifesciences India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 89.11 Cr.. The value appears strong and on an upward trend. It has increased from 84.60 Cr. (Dec 2024) to 89.11 Cr., marking an increase of 4.51 Cr..
• For Expenses, as of Mar 2025, the value is 81.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 71.85 Cr. (Dec 2024) to 81.69 Cr., marking an increase of 9.84 Cr..
• For Operating Profit, as of Mar 2025, the value is 7.42 Cr.. The value appears to be declining and may need further review. It has decreased from 12.75 Cr. (Dec 2024) to 7.42 Cr., marking a decrease of 5.33 Cr..
• For OPM %, as of Mar 2025, the value is 8.33%. The value appears to be declining and may need further review. It has decreased from 15.07% (Dec 2024) to 8.33%, marking a decrease of 6.74%.
• For Other Income, as of Mar 2025, the value is 2.34 Cr.. The value appears strong and on an upward trend. It has increased from 0.06 Cr. (Dec 2024) to 2.34 Cr., marking an increase of 2.28 Cr..
• For Interest, as of Mar 2025, the value is 2.03 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.14 Cr. (Dec 2024) to 2.03 Cr., marking a decrease of 0.11 Cr..
• For Depreciation, as of Mar 2025, the value is 3.80 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.76 Cr. (Dec 2024) to 3.80 Cr., marking an increase of 0.04 Cr..
• For Profit before tax, as of Mar 2025, the value is 3.93 Cr.. The value appears to be declining and may need further review. It has decreased from 6.91 Cr. (Dec 2024) to 3.93 Cr., marking a decrease of 2.98 Cr..
• For Tax %, as of Mar 2025, the value is 11.45%. The value appears to be improving (decreasing) as expected. It has decreased from 29.81% (Dec 2024) to 11.45%, marking a decrease of 18.36%.
• For Net Profit, as of Mar 2025, the value is 3.48 Cr.. The value appears to be declining and may need further review. It has decreased from 4.86 Cr. (Dec 2024) to 3.48 Cr., marking a decrease of 1.38 Cr..
• For EPS in Rs, as of Mar 2025, the value is 9.82. The value appears to be declining and may need further review. It has decreased from 18.09 (Dec 2024) to 9.82, marking a decrease of 8.27.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:01 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:20 am

Below is a detailed analysis of the balance sheet data for SMS Lifesciences India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
• For Reserves, as of Mar 2025, the value is 194.00 Cr.. The value appears strong and on an upward trend. It has increased from 174.00 Cr. (Mar 2024) to 194.00 Cr., marking an increase of 20.00 Cr..
• For Borrowings, as of Mar 2025, the value is 86.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 101.00 Cr. (Mar 2024) to 86.00 Cr., marking a decrease of 15.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 107.00 Cr.. The value appears to be improving (decreasing). It has decreased from 113.00 Cr. (Mar 2024) to 107.00 Cr., marking a decrease of 6.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 390.00 Cr.. The value appears to be improving (decreasing). It has decreased from 391.00 Cr. (Mar 2024) to 390.00 Cr., marking a decrease of 1.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 232.00 Cr.. The value appears strong and on an upward trend. It has increased from 223.00 Cr. (Mar 2024) to 232.00 Cr., marking an increase of 9.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 6.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 158.00 Cr.. The value appears to be declining and may need further review. It has decreased from 161.00 Cr. (Mar 2024) to 158.00 Cr., marking a decrease of 3.00 Cr..
• For Total Assets, as of Mar 2025, the value is 390.00 Cr.. The value appears to be declining and may need further review. It has decreased from 391.00 Cr. (Mar 2024) to 390.00 Cr., marking a decrease of 1.00 Cr..

Notably, the Reserves (194.00 Cr.) exceed the Borrowings (86.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for SMS Lifesciences India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 66.51. This value is within the healthy range. It has increased from 30.08 (Mar 24) to 66.51, marking an increase of 36.43.
• For Diluted EPS (Rs.), as of Mar 25, the value is 66.51. This value is within the healthy range. It has increased from 30.08 (Mar 24) to 66.51, marking an increase of 36.43.
• For Cash EPS (Rs.), as of Mar 25, the value is 111.56. This value is within the healthy range. It has increased from 70.34 (Mar 24) to 111.56, marking an increase of 41.22.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 650.15. It has increased from 640.48 (Mar 24) to 650.15, marking an increase of 9.67.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 650.15. It has increased from 640.48 (Mar 24) to 650.15, marking an increase of 9.67.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,140.22. It has increased from 1,012.00 (Mar 24) to 1,140.22, marking an increase of 128.22.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 165.05. This value is within the healthy range. It has increased from 115.57 (Mar 24) to 165.05, marking an increase of 49.48.
• For PBIT / Share (Rs.), as of Mar 25, the value is 115.44. This value is within the healthy range. It has increased from 66.16 (Mar 24) to 115.44, marking an increase of 49.28.
• For PBT / Share (Rs.), as of Mar 25, the value is 86.63. This value is within the healthy range. It has increased from 32.57 (Mar 24) to 86.63, marking an increase of 54.06.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 61.96. This value is within the healthy range. It has increased from 20.93 (Mar 24) to 61.96, marking an increase of 41.03.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 66.51. This value is within the healthy range. It has increased from 30.07 (Mar 24) to 66.51, marking an increase of 36.44.
• For PBDIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 11.42 (Mar 24) to 14.47, marking an increase of 3.05.
• For PBIT Margin (%), as of Mar 25, the value is 10.12. This value is within the healthy range. It has increased from 6.53 (Mar 24) to 10.12, marking an increase of 3.59.
• For PBT Margin (%), as of Mar 25, the value is 7.59. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 7.59, marking an increase of 4.38.
• For Net Profit Margin (%), as of Mar 25, the value is 5.43. This value is within the healthy range. It has increased from 2.06 (Mar 24) to 5.43, marking an increase of 3.37.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.83. This value is below the healthy minimum of 8. It has increased from 2.97 (Mar 24) to 5.83, marking an increase of 2.86.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.23. This value is below the healthy minimum of 15. It has increased from 5.14 (Mar 24) to 10.23, marking an increase of 5.09.
• For Return on Capital Employeed (%), as of Mar 25, the value is 14.07. This value is within the healthy range. It has increased from 8.13 (Mar 24) to 14.07, marking an increase of 5.94.
• For Return On Assets (%), as of Mar 25, the value is 5.15. This value is within the healthy range. It has increased from 2.32 (Mar 24) to 5.15, marking an increase of 2.83.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. It has decreased from 0.18 (Mar 24) to 0.09, marking a decrease of 0.09.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has decreased from 0.55 (Mar 24) to 0.42, marking a decrease of 0.13.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.88. It has increased from 0.77 (Mar 24) to 0.88, marking an increase of 0.11.
• For Current Ratio (X), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 24) to 1.06, marking a decrease of 0.01.
• For Quick Ratio (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.51 (Mar 24) to 0.58, marking an increase of 0.07.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 4. It has increased from 1.79 (Mar 24) to 2.02, marking an increase of 0.23.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 4.98 (Mar 24) to 0.00, marking a decrease of 4.98.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 1.88 (Mar 24) to 0.00, marking a decrease of 1.88.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 95.02 (Mar 24) to 0.00, marking a decrease of 95.02.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 98.12 (Mar 24) to 0.00, marking a decrease of 98.12.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 5.73. This value is within the healthy range. It has increased from 3.44 (Mar 24) to 5.73, marking an increase of 2.29.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.15. This value is within the healthy range. It has increased from 1.62 (Mar 24) to 3.15, marking an increase of 1.53.
• For Enterprise Value (Cr.), as of Mar 25, the value is 424.63. It has increased from 318.25 (Mar 24) to 424.63, marking an increase of 106.38.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.04 (Mar 24) to 1.23, marking an increase of 0.19.
• For EV / EBITDA (X), as of Mar 25, the value is 8.51. This value is within the healthy range. It has decreased from 9.11 (Mar 24) to 8.51, marking a decrease of 0.60.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.67 (Mar 24) to 0.94, marking an increase of 0.27.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 95.01 (Mar 24) to 0.00, marking a decrease of 95.01.
• For Price / BV (X), as of Mar 25, the value is 1.66. This value is within the healthy range. It has increased from 1.16 (Mar 24) to 1.66, marking an increase of 0.50.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.67 (Mar 24) to 0.94, marking an increase of 0.27.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness